Non-covid mRNA Vaccine and Therapeutics Market Size is valued at USD 370 Mn in 2024 and is predicted to reach USD 1,684.80 Mn by the year 2031 at an 24.20% CAGR during the forecast period for 2024-2031.
Non-covid-19 mRNA therapeutics involve using synthetic mRNA to instruct cells to produce specific proteins for treating or preventing diseases. This approach allows for precise targeting by encoding therapeutic proteins or antigens, helping treat conditions like cancer, genetic disorders, and infectious diseases. For instance, mRNA can be designed to stimulate the immune system against cancer cells or replace missing proteins in genetic disorders. Unlike traditional vaccines that use weakened pathogens, mRNA vaccines deliver genetic instructions to prompt the body to produce a harmless piece of a pathogen, triggering an immune response.
The applications of non-covid mRNA vaccine and therapeutics are expanding into cancer treatment, genetic disorders, and infectious diseases like influenza and Zika virus. Additionally, mRNA technology is being explored to modulate immune responses in autoimmune diseases. A key factor driving growth in this area is advancements in delivery technologies like lipid nanoparticles (LNPs), which improve the stability and precision of mRNA therapeutics. These innovations make mRNA a promising option for chronic disease treatment by enhancing targeting and reducing immunogenicity issues.
The non-covid mRNA vaccine and therapeutics market is segmented by product type, therapeutic area, route of administration. By product type the market is segmented into mRNA therapeutic, mRNA vaccines. By therapeutic area market is categorized into infectious diseases, oncological disorders, other disorders. Infectious disease sub segmented into influenza, respiratory syncytial virus (RSV), cytomegalovirus, and others. By route of administration the market is categorized into intravenous, intramuscular, intranasal, and others.
The predominant driver of the non-covid mRNA vaccine and therapeutics market is the mRNA vaccines segment with many major reasons attached to it. It has broad applicability to vaccines targeting various cancers and infectious diseases like influenza, Zika, and rabies, hence giving it versatility and adaptability to emerging health threats. The mRNA vaccine improves efficacy and safety and takes it into cells with greater ease for both prevention and therapy, improved by technological advances in this case of delivery systems through lipid nanoparticles. Another important attribute of mRNA technology is that it allows for more rapid development and scalability, thereby making a tool that can be rapidly applied to an outbreak, placing this technology at the forefront of vaccine development
The infectious diseases segment in the non-covid mRNA vaccine and therapeutics market has been growing significantly because of a few key factors. The agility of the technology in adapting to a variety of pathogens has led to the development of mRNA vaccines for a vast number of diseases, such as influenza, HIV, Zika virus, and RSV. Advances in mRNA-based clinical trials, with several candidates at the phase II and III stage, have given added momentum and increased investment into the applications of mRNA.
The strongest area that leads the market in North America for non-covid mRNA vaccine and therapeutics would be because of a well-developed research and development infrastructure, significant funding, and a friendly regulatory environment. Additionally, the U.S. is host to one of the most robust R&D ecosystems, with many pharmaceutical companies, biotech firms, and academic institutions that drive innovation in the field of mRNA technology. Massive funding from the public and private sectors supports a diversified pipeline, such as those for infectious diseases and cancer therapies. Moreover, the U.S. FDA's fast-tracked review program further accelerates the approval and subsequent commercialization of new therapeutics, adding more momentum to the market's growth in the region.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 370.0 Mn |
|
Revenue Forecast In 2031 |
USD 1,684.80 Mn |
|
Growth Rate CAGR |
CAGR of 24.20% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product Type, Therapeutic Area, Route of Administration and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
|
Competitive Landscape |
CureVac, Anima Biotech, Arcturus Therapeutics, BioNTech (Pfizer), eFFECTOR Therapeutics, Inc., eTheRNA, Ethris (AstraZeneca), H3 Biomedicine Inc. (Eisai Inc.), In-Cell-Art, Ionis Pharmaceuticals, Inc., Kernal Biologics, Moderna, RNAimmune (Sirnaomics), Silence Therapeutics, Skyhawk Therapeutics, Inc., Stemirna Therapeutics Co., Ltd., Tiba Biotechnology, Translate Bio Sanofi), Ziphius Therapeutics NV |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Non-covid mRNA Vaccine and Therapeutics Market by Product Type
Non-covid mRNA Vaccine and Therapeutics Market by Therapeutic area
Non-covid mRNA Vaccine and Therapeutics Market by Route of Administration
Non-covid mRNA Vaccine and Therapeutics Market by Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
